Incretin therapy in the form of GLP1 receptor agonists or GLP1/GIP dual agonists (GLP1-RA) are established in the management of Type 2 diabetes (T2D) as well as the management of overweight/obesity. There is also increasing evidence that people with overweight/obesity and T2D are at a higher risk of eating disorders. However, screening for eating disorders is not usual practice for health care professionals prescribing these medications. This means that there are potentially a large number of people with eating disorders or at high risk of eating disorders that are taking these medications. There are a lot of opinions (some very strong), on whether or not people with eating disorders (or at risk of eating disorders) should be offered these medications that have been demonstrated to greatly benefit glycaemia and assist in weight loss. While there are a lot of posts on social media and many podcasts for either side of the argument, there is limited scientific evidence to support either the use or avoidance of these medications. The evidence around the possible use or danger of using GLP1-RA for binge eating disorders will also be discussed. Given the emerging pipeline of medications that are likely to result in even greater weight loss, and the wider use of incretin therapy, this talk will discuss the evidence around the safety as well as the pros and cons of using GLP1-RA in people with or at risk of an eating disorder.